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Abstract
Background: The pathological hallmarks of Parkinson’s disease (PD) include the presence of alpha-synuclein
(a-syn) rich Lewy bodies and neurites and the loss of dopaminergic (DA) neurons of the substantia nigra (SN).
Animal models of PD based on viral vector-mediated over-expression of a-syn have been developed and show
evidence of DA toxicity to varying degrees depending on the type of virus used, its concentration, and the
serotype of vector employed. To date these models have been variable, difficult to reproduce, and slow in their
evolution to achieve a desired phenotype, hindering their use as a model for testing novel therapeutics. To
address these issues we have taken a novel vector in this context, that can be prepared in high titer and which
possesses an ability to produce neuronally-directed expression, with expression dynamics optimised to provide a
rapid rise in gene product expression. Thus, in the current study, we have used a high titer chimeric AAV1/2
vector, to express human A53T a-syn, an empty vector control (EV), or green fluorescent protein (GFP), the latter to
control for the possibility that high levels of protein in themselves might contribute to damage.
Results: We show that following a single 2 μl injection into the rat SN there is near complete coverage of the
structure and expression of A53T a-syn or GFP appears throughout the striatum. Within 3 weeks of SN delivery of
their respective vectors, aggregations of insoluble a-syn were observed in SN DA neurons. The numbers of DA
neurons in the SN were significantly reduced by expression of A53T a-syn (52%), and to a lesser extent by GFP
(24%), compared to EV controls (both P < 0.01). At the level of the striatum, AAV1/2-A53T a-syn injection produced
dystrophic neurites and a significant reduction in tyrosine hydroxylase levels (by 53%, P < 0.01), this was not seen
in the AAV1/2-GFP condition.
Conclusions: In the current implementation of the model, we recapitulate the primary pathological hallmarks of
PD, although a proportion of the SN damage may relate to general protein overload and may not be specific for
A53T a-syn. Future studies will thus be required to optimise the dose of AAV1/2 employed before fully
characterizing this model. The dynamics of the evolution of the pathology however, provide advantages over
current models with respect to providing an initial screen to assess efficacy of novel treatments that might
prevent/reverse a-syn aggregation.
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Background
A pathological feature of Parkinson’s disease (PD), irre-
spective of etiology, is the presence of intraneuronal
Lewy bodies and Lewy neurites. The appearance of
Lewy bodies in different brain regions parallels the
development of symptom severity [1-3]. Lewy bodies are
composed of at least 45 identified proteins and lipids,
although the most significant contribution is made by
a-synuclein (a-syn) [4-8]. Loss of dopamine (DA) neu-
rons and the presence of Lewy bodies in the substantia
nigra (SN) together provide the definitive diagnosis of
PD [9]. The precise role for a-syn in the CNS, however,
has yet to be determined. a-syn binds readily to lipids
[10] and appears to be associated with vesicles in the
presynaptic terminal [11-13] suggesting that the physio-
logical role of a-syn might be related to vesicular release
at the lipid membrane.
Human familial and sporadic cases of PD and animal
models demonstrate that, in some form, a-syn contri-
butes to the development of PD. Thus, familial forms of
PD can be caused by mutations of a-syn (A53T, A30P,
and E46K) [14-16] as well as by duplication and triplica-
tion of the wildtype (Wt) allele, SNCA [17-19]. Post-
mortem analyses of sporadic forms of PD reveal Lewy
bodies heavily stained for a-syn, although the mechan-
ism of their production is unclear. Less convincing, per-
haps, though still supportive of a role for a-syn in
dopaminergic dysfunction in PD, are transgenic mice
over-expressing a-syn. These animals show motor
abnormalities and impairment in striatal DA release,
though no overt loss of DA neurons [13,20,21]. Over-
expression of a-syn (whether Wt or mutated), through
the use of viral vectors, in the rodent [22-25] and pri-
mate [26,27] SN, has provided a more clear indication
of toxicity, with DA neuron loss in the SN, dystrophic
neurites, reductions in striatal DA, and motor behaviour
impairments. Taken together, these data all support the
hypothesis that a-syn is toxic to DA neurons.
In normal human, a-syn is evenly distributed through-
out the neuropil [28]. In PD, however, staining in sur-
viving dopamine neurons is largely in clumps, or
aggregates, that are seen throughout the soma. A large
proportion of these a-syn aggregates are resistant to
protein digestion techniques and considered to be inso-
luble [29-32]. It is tempting to speculate that aggrega-
tion of a-syn is a toxic process in PD and thus, that
solubilising, or de-aggregating would be an effective
approach to disease modification. However, using post-
mortem tissue, it is difficult to discern whether the neu-
rons that have already died in PD had a-syn aggregates
similar to those that have survived. Animal models of
synucleinopathy are thus important to critically assess
the relevance of targeting a-syn aggregation as a therapy
for PD. While the gene delivery based animal models of
synucleinopathy, have proved better than transgenic
models, in so far as reproducing overt nigrostriatal
damage, limitations exist. Thus, to date, none of the
viral vector models, whether based upon adeno-asso-
ciated viral vectors (AAV) or lentiviruses have proved
optimal for addressing these questions or providing a
reliable platform upon which drug discovery pro-
grammes might usefully build. Thus, in some cases the
timeframe for development of damage is long (8-16
weeks) [22,23,25], and in others there is high variability
within studies [24,27]. We propose that these limitations
are purely technical, relating to the specifics of the virus
and that a delivery vector, with a strong promoter, and
selective neuronal expression, if produced in high titer
could produce a model of PD synucleinopathy that
would have even greater utility. Our preferred model
would have the following properties: (1) high levels of
expression of a-syn in SN and striatum, after SN deliv-
ery (2) pathology that developed over a time period that
allowed investigation of effects of manipulations
initiated before and after a-syn damage had occurred
(3) relatively rapid evolution of the model, 3-6 wks, to
minimise logistical challenges in running studies with
the model (4) an evolving behavioural deficit (5) pathol-
ogy that had characteristics similar to Lewy bodies and
neurites e.g. intraneuronal inclusions of a-syn in the SN
and dystrophic neurites in the striatum and (6) damage
that was specific for a-syn and not purely a result of
general over-expression of a protein.
As a first step towards achieving these goals we have
developed a novel AVV model of PD alpha synucleino-
pathy. This vector is based on combining the distinct
advantages of serotype 2 (neuronal tropism, ability to
produce high titers, and to purify on a heparin sulphate
column) with that of serotype 1 (excellent ability to
penetrate brain tissue), using a chimeric approach to its
construction. Thus, AAV1/2 is a vector that expresses
both AAV serotype 1 and 2 on the viral capsid in a one
to one ratio (details in methods section).
In the current study we have used this AAV1/2 vector
to produce a rat model of PD based on the targeted
expression of human A53T a-syn in the SN and using
GFP and an empty vector as controls. The principle aim
of this study was to provide an initial assessment of
whether these vectors can drive expression in neurons
of the substantia nigra, whether that protein is trans-
ported to terminals in the striatum and whether such
expression is associated with aggregate-like pathology
and loss of dopaminergic phenotype. To this end we
report that high titer AAV1/2 vectors produce a rela-
tively rapid course (3 weeks) of dopaminergic nigrostria-
tal pathology in the presence of a-syn aggregates and
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dystrophic axonal morphology and that GFP also shows
evidence of toxicity.
Results
Expression of GFP and human A53T alpha-synuclein
along the nigrostriatal path
Delivery of AAV1/2-A53T alpha-synuclein to the SN of
rats produced widespread expression in TH-immunor-
eactive neurons across the entire rostral-caudal axis of
the SN. Of the SN neurons still expressing TH, the vast
majority of them co-localized with human a-syn (Figure
1G). Co-localization of TH and a-syn within a single
neuron was confirmed by high magnification confocal
imaging and after review of z-stacks (Figure 1H). Aggre-
gation of alpha-synuclein within the cytoplasm of TH-
immunoreactive neurons is shown in Figure 1H and
could be seen in most a-syn/TH positive cells.
Expression of GFP following delivery of AAV1/2-GFP
to the SN was also shown to co-localize with TH-immu-
noreactive neurons (confirmed with z-stacks) through-
out the SN (Figure 1C, D). GFP aggregates were
observed in the majority of cells within the SN that
expressed TH (Figure 1D).
A pathological feature of PD is that a significant pro-
portion of a-syn inclusions in nigral neurons are consid-
ered to be aggregated (insoluble inclusions) [5,7,28]. In
order to evaluate the solubility of the a-syn deposits
seen in this model we conducted a proteinase K (PK)
digestion on midbrain sections from AAV1/2 A53T a-
syn rats. We found that the majority a-syn inclusions in
our model were resistant to PK digestion and could
thus be considered insoluble aggregates (Figure 2).
Transport of viral vector mediated GFP or alpha-synu-
clein along the nigrostriatal projection was indicated by
expression in terminals throughout the striatum. Figure
3A, B shows that both GFP and alpha-synuclein were
transported along axons from neurons of the SN and
terminating in the striatum. Expression was observed
from the most anterior to the most posterior extent of
the striatum.
Nigral delivery of AAV1/2-A53T alpha-synuclein and
AAV1/2-GFP produce neuronal loss in the SN
Three weeks following surgical delivery of AAV1/2 vec-
tors to the rat SN there were significant differences in
the amount of TH-immunoreactive neurons present
quantified using unbiased stereology [F(2,12) = 26.15,
P < 0.0001] (Figure 4A-D). To serve as a control, identi-
cal AAV1/2-empty vectors were delivered in the same
manner and concentration. Post-hoc analysis revealed
that rats that received AAV1/2-A53T a-syn had signifi-
cantly less TH-immunoreactive neurons compared to
those injected with either AAV1/2-empty vector (52%
reduction, P < 0.001) and GFP (37% reduction, P <
0.01). Furthermore, there were significantly less TH-
immunoreactive neurons in rats receiving AAV1/2-GFP
compared to those that received AAV1/2-empty vector
controls (24% reduction, P < 0.05). To confirm that the
AAV1/2-EV was not toxic to DA neurons we counted
TH-immunoreactive neurons in the SN opposite to the
Figure 1 Colocalization of tyrosine hydroxylase and alpha-synuclein or GFP in the substantia nigra. Immunofluorescent staining of
tyrosine hydroxylase (A, E), GFP (B), and human alpha-synuclein (F) 3 weeks following AAV1/2 injections. Panels C and G represent merged
images of A + B and E + F, respectively. Panels D and H represent high power confocal images revealing aggregates of human alpha-synuclein
and GFP within a TH neuron of the substantia nigra and confirmed by the orthogonal view of each panel. Scale bar is 500 μm.
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Figure 2 Alpha-synuclein deposits in nigral neurons are insoluble aggregates. Midbrain sections from rats injected with AAV1/2 A53T
a-syn were treated with proteinase K (B, PK+) or the buffer used to dissolve PK (A, PK-) and subsequently immunostained for human a-syn to
determine its solubility. Panel A (PK-) shows that a-syn expression fills the substantia nigra expressing in both nigral neurons and neurites. In
panel B, following PK digestion, many neurons maintain expression of a-syn aggregates (insoluble a-syn), while the neurites appear to have
been largely cleared (soluble a-syn). Arrows point to examples of a-syn filled neurons. Scale bar in panel A is 200 μm.
Figure 3 Expression of transgenes in the striatum. Both GFP and human alpha-synuclein were widely expressed throughout the striatum 3
weeks following delivery of AAV1/2 to the substantia nigra. Scale bar in panel A is 500 μm.
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Figure 4 Tyrosine hydroxylase and NeuN cell counting in the substantia nigra. Three weeks following delivery of AAV1/2 to the substantia
nigra there is significant reductions in the number of TH-immunoreactive neurons and NeuN-immunoreactive neurons for both alpha-synuclein
and GFP treated animals compared to empty vector controls. AAV1/2 A53T alpha-synuclein produced significantly greater TH and NeuN cell loss
compared to the GFP group. *P < 0.05 cf. empty vector; **P < 0.01 cf. empty vector; *** P < 0.001 cf. empty vector; ##P < 0.01 cf. GFP; scale bar
is 1000 μm.
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injected side and showed that there was no significant
difference between hemispheres (t[8] = 1.09, P > 0.05).
Further analysis was conducted to determine whether
viral vector mediated reductions in TH-immunoreactive
neurons of the SN were due to a loss in phenotypic
expression or neuronal death. To address this we per-
formed stereological cell counts in the SN that was
immunohistochemically labelled with a universal neuron
marker, NeuN. The numbers of NeuN-immunoreactive
cells were significantly different across treatment groups
[F(2,12) = 33.29, P < 0.0001] (Figure 4E-H). Delivery
with AAV1/2-A53T alpha-synuclein produced a 42%
and a 29% decrease in NeuN-immunoreactive cells com-
pared to AAV1/2-empty vector (P < 0.01) and AAV1/2-
GFP (P < 0.01) treated groups respectively. Animals
receiving AAV1/2-GFP showed a significant reduction
in NeuN-immunoreactive cells compared to AAV1/2-
EV controls (19% reduction, P < 0.01).
Expression of A53T alpha synuclein, but not GFP, reduces
tyrosine hydroxylase expression in the striatum
In the striatum, the degree of TH expression was assessed
using optical density (OD) measurements of immuno-
labelled tissue. Three anatomical levels were assessed (pre-
commissural, commissural, and post-commissural; see
Figure 5) and for each level the contralateral striatum was
also assessed. Final values represent the average of the 3
anatomical levels taken as a percentage of the average of
each corresponding contralateral level. There were
significant differences in TH-OD across groups [F(2,13) =
18.57, P < 0.001] (Figure 5C). Animals injected with
AAV1/2-A53T a-syn showed significant reductions in
TH-OD compared to AAV1/2-EV (P < 0.01) and AAV-1/
2-GFP treated groups (P < 0.01), while no change in TH-
OD was observed in animals that received AAV1/2 GFP
compared to EV controls (P > 0.05, NS) (Figure 5).
To see whether the observed reduction in TH expres-
sion was maintained, we analyzed tissues that had been
exposed to AAV1/2-A53T a-syn for an additional 3
weeks. Thus, 6 weeks following injection of AAV1/2-
A53T a-syn we found that striatal TH remained signifi-
cantly reduced (t[8] = 2.57, P < 0.05; 167 ± 21 vs. 223 ± 4
[mean optical density ± SEM]) compared to its respective
non-injected side. Further analysis of dopaminergic fibres
was conducted using dopamine transporter (DAT) as a
marker to support the apparent loss of nigrostriatal pro-
jections at this timepoint. We found that striatal DAT
levels (nCi/g) were also significantly reduced (t[8] = 2.81,
P < 0.05; 287 ± 65 vs. 483 ± 24 [mean optical density ±
SEM]) compared to its respective non-injected side.
Dystrophic axonal morphology is present in the striatum
of AAV1/2 A53T alpha-synuclein injected rats
Dystrophic and swollen neurites, labelled with a human
specific a-syn antibody, were prevalent throughout the
striatum of AAV1/2-A53T a-syn injected animals
(Figure 6A). Similar morphology was observed in these
same animals using TH-immunoreactive, although,
Figure 5 Tyrosine hydroxylase immunostaining in the striatum. AAV1/2 human A53T alpha-synuclein produced significant reductions in the
optical density measurements of tyrosine hydroxylase (TH) compared to empty vector and GFP treated groups 3 weeks following AAV1/2
injection into the substantia nigra. **P < 0.01 c.f. empty vector; ##P < 0.01 c.f. GFP. Scale bar in panel A is 500 μm.
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given the significant decrease in TH optical density in
this region (Figure 5), less fibres were strongly labelled
(data not shown). No abnormal morphological features
were seen in GFP-immunoreactive striatal tissue and
fibres appeared similar to TH-immunoreactive fibres of
the AAV1/2-EV treated animals (Figure 6B, C).
Discussion
The objective of the current study was to develop a rat
model of Parkinson’s disease based on the targeted over
expression of human A53T a-syn that produced pathol-
ogy in a time frame amenable to initial in vivo evaluation
of potential therapeutics. We show that within 3 weeks
of injection of high titer AAV1/2 viral vectors (5.1 × 1012
gp/ml) into the SN there are significant signs of dopami-
nergic toxicity in the nigrostriatal pathway.
Delivery of a single 2 μl injection of AAV1/2 A53T
a-syn to the rat SN produced excellent anatomical cover-
age of the target region, the SN. Thus, a-syn expression
was observed in the vast majority of TH-immunoreactive
neurons spanning the anterior-posterior and dorso-ven-
tral boundaries of the SN. Transport of a-syn and GFP
by DA neurons of the SN was determined by examining
fibre staining in the primary target structure, the stria-
tum. Indeed, the entire striatum was filled with human
a-syn or GFP stained fibres, indicating that A35T a-syn
and GFP are able to travel along the nigrostriatal path
and confirms that the majority of SN TH-immunoreac-
tive neurons remaining are producing the vector
mediated proteins. Thus, with respect to coverage of SN
DA neurons and their axons projecting to the striatum,
the AAV1/2 construct utilized in this experiment was
highly effective. It is likely that the properties of the sero-
type 1 component of our construct and the high titer
that could be purified afforded the AAV1/2 its ability to
penetrate brain tissue with such efficacy [33,34]. In a
study by McFarland et al (2009), several AAV serotypes
of similar concentration were compared, and serotype 1
had superior coverage of expression at the level of the SN
compared to others (serotypes 2, 5, and 8) [33]. Use of
the AAV2/5 construct with titers greater than those used
here (6.2 - 6.7 × 1013 gc/ml) has also produced coverage
of the SN in similar magnitudes using only a single 2 μl
injection into the SN [35] and may provide an alternative
means of producing models with excellent anatomical
coverage, though the impact of such high titers on non-
specific damage remains to be evaluated (see below).
Three weeks after delivery of AAV1/2-A53T a-syn,
aggregates of human a-syn were observed in nigral TH-
immunoreactive cells. Aggregates of a-syn were deter-
mined to be insoluble as indicated by being resistant to
proteinase K digestion, a cardinal feature observed in
PD [7,28,29,32]. There was a reduced number of nigral
TH-immunoreactive neurons, as well as reduction in
total neuronal (NeuN) number, and, within the striatum,
a loss of TH-immunoreactive fibre density and the pre-
sence of a-syn/TH-positive dystrophic neurites. Further-
more, this reduction in TH fibre density was present
through 6 weeks with a concomitant reduction in stria-
tal DAT demonstrating a persistence of effect. Thus, the
approach of AAV1/2 delivery of A53T a-syn was able
to replicate, in only three weeks, the major pathological
hallmarks of PD. The model used here is not the first
AAV-based delivery of a-syn to replicate a-syn aggrega-
tion, dystrophic neurites, and similar patterns of nigral
cell loss. This has been previously demonstrated in
other AAV a-syn rat models [22,23,25,35], although
with longer durations to achieve endpoints (8-16 weeks)
and variable degrees of cell loss (32-50%). However, the
magnitude of the losses (53% reduction in SN DA neu-
rons), the low variability (n = 6/group) and the short
time course of development (3 weeks) of the pathologies
seen in the current study, highlight some of the poten-
tial advantages of using a high titer AAV1/2 vector
when considering a model for assessing potential thera-
peutics targeting the toxicity of a-syn in PD.
Figure 6 Axon morphology in the striatum of AAV1/2 treated rats. Delivery of AAV1/2 human A53T alpha-synuclein to the substantia nigra
produces dystrophic and bulging neurites in the striatum 3 weeks later. These changes in axonal morphology do not appear in the AAV1/2 GFP
(GFP-immunoreactive [-ir]) or empty vector (represented by tyrosine hydroxylase-immunoreactive [ir]) treated animals. Arrows point to evidence
of human alpha-synuclein positive dystrophic neurites; scale bar is 50 μm.
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AAV1/2 delivery of GFP was employed to control for
the effects of high expression of any exogenous protein.
This control demonstrated that the high titer of AAV1/
2-GFP employed here caused significant nigral dopami-
nergic toxicity and thus should be considered when
interpreting the toxic effects produced by delivery of
AAV1/2 a-syn or other high titer vectors. The toxicity
of AAV1/2-GFP however, could not account for all the
A53T a-syn induced damage in the nigra, being signifi-
cantly less, and being limited to the SN (no loss in stria-
tal TH-immunoreactive or signs of dystrophic neurites).
Thus, three weeks following the delivery of AAVs,
aggregates of both human a-syn and GFP were observed
in TH-immunoreactive neurons of the SN. Aggregates
were seen in the majority of cells expressing both TH
and a-syn or GFP. Unbiased stereology demonstrated
that AAV1/2-A53T a-syn and, to a lesser extent,
AAV1/2-GFP resulted in significant reductions in TH-
immunoreactive neurons compared to AAV1/2-EV
injected rats. In a recent study by Sanchez-Guajardo
et al. (2010) AAV2/5 was used to deliver human a-syn
(6.2 × 1012 gp/ml) or GFP (7.9 × 1012 gp/ml) as a con-
trol. The results of that study showed that GFP and
a-syn expression produced ~20% and 50% SN DA neu-
ron loss, respectively. These data support those shown
here, in that expression of a control protein can be toxic
and needs to be considered in the interpreation of the
results.
To determine whether the TH-immunoreactive cell
loss in the SN of the current study was indicative of a
down-regulation of TH or frank neuronal cell loss,
stereological assessment of NeuN-positive cells was
performed [22,36,37]. NeuN cell counts were also signif-
icantly reduced in AAV1/2-A53T a-syn and AAV1/2-
GFP injected animals when compared to AAV1/2-EV
controls. In both cases (TH and NeuN cell number), the
rats that received AAV1/2-A53T a-syn had significantly
greater cell loss than AAV1/2-GFP administered ani-
mals. The toxicity of AAV1/2-GFP is unlikely to result
from toxicity due to the vector itself, as, in so far as the
dependent measures used in this study, injection of
AAV1/2-EV produced no evidence of degeneration, in
either the SN or the striatum. This suggests that over-
loading of the control protein might, in itself, be the
cause of some of the SN damage seen with AAV1/
2-GFP used at this titer. Indeed, a similar effect of GFP
toxicity to SN DA neurons has been reported with the
use of AAV8 (4 μl of 1 × 1010 vector genomes/ml) four
weeks following injection [38]. Burdening the DA neu-
rons of the SN with excessive protein likely reduces
their fitness and leads to their demise. Cellular systems,
lysosomal and ubiquitin proteasome, designed to deal
with protein turnover have been shown to be signifi-
cantly more active in DA neurons following viral vector
mediated expression of a-syn and also in PD patients
[29], although to no avail, indicating that insufficient
clearance of unwanted or misfolded proteins may pose a
significant threat. These findings highlight the impor-
tance of not only EV controls, which are often used, but
also control protein vectors to define whether general-
ised protein overload underlies damage attributed to
purported toxic proteins such as a-syn.
However, while there may be a non-a-syn-specific
component to SN damage caused by delivery of AAV1/
2-A53T a-syn, the striatal damage, loss of TH and dys-
trophic neurite pathology, appears to be specific to the
expression of A53T a-syn. Thus, if this high titer
AAV1/2 model were to be used, for instance to evaluate
novel therapeutic strategies targeting a-syn, it might be
appropriate to concentrate on striatal endpoints. There
currently exist several classes of drugs that could be
used in this initial screen that have been shown to
reduce a-syn levels in vivo. For example, one of the sta-
tin drugs, lovastatin, was reported to reduce a-syn levels
in the cortex of transgenic mice that overexpress a-syn
[39]; rifampicin (a bacterialcidal antibiotic) has been
shown to reduce established a-syn aggregate load and
associated insoluble oligomers in a mouse model of
multiple system atrophy that resulted in a decrease in
neurodegeneration [40]; and finally rapamycin, a macro-
lytic lactone, that has been shown to reduce a-syn levels
ostensibly via activation of autophagy [41,42]. However,
in future implementations of this model, it may be use-
ful to evaluate lower titers of AAV1/2 to define if such
a dose can be identified which will produce SN toxicity
that can be completely ascribed to A53T a-syn delivery
and have no component that might be caused by gener-
alised protein overload.
Conclusions
Clinical and experimental evidence points towards the
presence of a-syn aggregates in catecholaminergic neu-
rons in PD as a contributing factor to reduced neuronal
health and ultimately cell death. Irrespective of etiology,
the vast majority of PD cases receiving post-mortem
evaluation show Lewy bodies and Lewy neurites which
stain heavily for a-syn [5]. This suggests that of the
multiple upstream mechanisms, whether of genetic and/
or non-genetic origin, responsible for PD, there appears
to be convergence that leads to synucleinopathy. Such
convergence defines a-syn as a key intervention point at
which therapeutics could broadly target PD. It remains
unclear whether the end product of a-syn accumulation,
the aggregated form in Lewy bodies, is toxic or whether
species leading up to this form should be the focus of
therapeutic strategies. In vivo models such as that
described here will prove useful in understanding which
types of therapies will be effective by providing a
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relatively rapid screening platform upon which to test
drugs capable of preventing aggregate formation or by
reversing/de-aggregating inclusions. Care must be taken
however, in interpreting actions where the damage can-
not be completely ascribed to the a-syn per se, where
there might be some role of generalised increased
demand on protein handling systems. Indeed, more
work is needed to refine models that do not generate
toxicity in the control protein condition. This will likely
require lower vector concentrations and a somewhat
longer time course. There may always be a balance
between non-specific toxicity and duration of evolution
of pathology. However, we could envisage an ideal
model based around the current AAV1/2 technology
where pathology and behavioural deficits, selective for
a-syn over generalised over-expression of protein,
evolved over a relatively short period of time, perhaps 6
weeks, but where there was an intermediate stage, per-
haps at 3 weeks, where there was functional disruption
of DA systems though in the absence of overt cell loss.
Treatments that were deemed efficacious in the rapid
onset model, such as that described here, could then be
further evaluated in a more protracted or progressive
model to define in greater detail their therapeutic
potential.
Methods
Animals and vector delivery
24 female Sprague Dawley rats (~280 g, Charles River)
were stereotaxically injected with either AAV1/2 empty
vector, GFP, or human A53T alpha-synuclein under iso-
flurane/oxygen anesthesia. In each case, a single 2 μl
injection of viral vector was delivered to the SN at a
rate of 0.2 μl/min according to the following coordi-
nates: AP, -5.2 mm; ML, -2.0 mm; DV, -7.5 mm (skull)
using a microinjector (Stoelting, Kiel, WI) and according
to the atlas of Paxinos and Watson (1997). Animals
were housed in pairs in a temperature controlled envir-
onment, kept on regular 12 hr light/dark cycle and
allowed food and water ad libitum. All procedures were
conducted under a permit that had received local
IACUC approval (University Health Network).
Vectors
Adeno associated vectors were custom ordered from Gen-
eDetect Ltd. (Auckland, New Zealand). Each vector was
driven by a chicken beta actin (CBA) promoter hybridized
with the cytomegalovirus (CMV) immediate early enhan-
cer sequence. In addition, a woodchuck post-transcrip-
tional regulatory element (WPRE) and the presence of a
bovine growth hormone (BGH) polyadenylation sequence
for high transcription following transduction was incor-
porated. Viral titers were 5.1 × 1012 genomic particles
(gp)/ml for each vector used and were determined by
quantitative PCR (Applied Biosystems 7900 QPCR) with
primers directed to the WPRE region incorporated within
the AAV expression cassette, thus representing the num-
ber of functional physical particles of AAV in the solution
containing the genome to be delivered. WPRE primers
used produced a 113 bp product and were as follows (5’ to
3’): FWD GGCTGTTGGGCACTGACAAT; REV CCGAA
GG GACGTAGCAGAAG. AAV1/2 is a chimeric vector
where the capsid expresses AAV1 and AAV2 serotype
proteins in a 1:1 ratio and use the inverted terminal
repeats (ITR’s) from AAV2 according to the following
scheme: ITR (from AAV2)——CMV/CBA promoter——
human A53T alpha-synuclein or GFP——WPRE-bGH-
polyA——ITR (from AAV2) [43]. Viral vectors were affi-
nity purified against immobilized heparin sulphate proteo-
glycan and concentrated by modified Iodixanol/cation
exchange/Q-Sepharose. Purity was verified by SDS-PAGE.
Three vectors were produced using this design, in the first,
the gene for mutated human alpha-synuclein was inserted,
this vector is termed AAV1/2-A53T a-syn, the second
vector expressed green fluorescent protein (GFP), AAV1/
2-GFP, and in the third vector the space for the gene was
left empty, AAV1/2-empty vector (EV). Similar AAV1/2
chimeric vectors have previously been used for other pur-
poses i.e. expressing proteins in experimental models of
Huntington’s disease and epilepsy [34,44].
Post-mortem measures
Immunohistochemistry Three weeks after AAV1/2
injection, animals were administered an overdose of
pentobarbital and killed by exsanguination with saline
followed by 4% paraformaldehyde, brains removed and
processed for immuno-labeling. Brains were sectioned
frozen in the coronal plane at a thickness of 40 μm on a
sliding microtome (Leica Microsystems Inc., Richmond
Hill, ON) and 6 series of sections were stored in cryo-
protectant (30% glycerol, 30% ethoxyethanol, 40% PBS).
A single series of sections were processed for visualiza-
tion of tyrosine hydroxylase (TH) and NeuN via the bio-
tin-labelled antibody procedure. Briefly, following several
washes in a PBS solution containing 0.2% Triton X-100
(PBS-T), endogenous peroxidase was quenched in a 3%
hydrogen peroxide solution and background staining
was then inhibited in a 10% normal goat serum/2%
bovine serum albumin solution. Tissue was then incu-
bated with primary antibodies overnight: rabbit anti-TH
antibody (1:1000, Pel-Freez, Rogers, AR), mouse anti-
NeuN antibody (1:200, Millipore, Billerica, MA). After
three washes in PBS-T, sections were sequentially incu-
bated in biotinylated goat anti-rabbit or mouse IgG
(1:300; Vector, Burlingame, CA) for 1 h and the Elite
avidin-biotin complex (ABC Kits; Vector, Burlingame,
CA) for 1 h separated by three washes in PBS. Immu-
nostaining was visualized following a reaction with 3,3-
diaminobenzidine (Vector, Burlingame, CA). Sections
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were then mounted on glass slides, allowed to dry,
dipped into dH20, dehydrated through graded alcohols
(70%, 95%, 100%), cleared in xylenes, and coverslipped
with DPX mounting medium (Electron Microscopy
Sciences, Hatfield, PA).
Triple label immunofluorescence (Confocal micro-
scopy, Zeiss Axioplan with LSM510META) to reveal
TH (1:1000, Pel-Freez, Rogers, AR) and human alpha-
synuclein (1:500, Zymed, San Fransico, CA) or GFP
(1:2000, Abcam, Cambridge, MA), and Hoechst (nuclear
stain) simultaneously to provide detail regarding co-
localization and whether expression was nuclear and/or
cytoplasmic. Images were taken throughout the Z-axis
to confirm co-localization of a-syn and GFP within indi-
vidual TH neurons.
Stereology TH and NeuN stained sections of the SN
were used for stereological estimation of dopamine neu-
ron numbers using optical fractionator from the Stereo
Investigator software package (v. 7, MBF Biosciences,
Williston, VT). The user was blinded to group assign-
ment by coded slides. Nine sections spanning the entire
anterior/posterior extent of the SN, separated by 240
μm (1/6 series), were used for counting. All TH-immu-
noreactive neurons of the SN (pars compacta and pars
reticulata) were included within each contour, of each
section. NeuN contours were closely matched with cases
used for TH [22]. Parameters used for TH stereological
counting were grid size, 300 μm × 300 μm; counting
frame, 80 μm × 80 μm, and 2 μm guard zones. Para-
meters used for NeuN stereological counting were grid
size, 480 μm × 480 μm; counting frame, 80 μm × 80
μm, and 2 μm guard zones. Tissue thickness was deter-
mined by the user at each counting site. All final values
represent estimated total by number weighted section
thickness and were only included if their Gunderson
coefficient of error (m = 1) was less than 0.09.
Proteinase K treatment Tissue sections from AAV1/
2-A53T a-syn rats containing the SN were treated with
proteinase K to determine whether the a-syn seen here
was soluble (non-aggregated) or insoluble (aggregated)
according to the method of Chu et al (2007 and 2009)
[28,29]. Briefly, sections were mounted and dried on
Permafrost+ glass slides for at least 8 hrs at 55°C. Sec-
tions were then briefly hydrated with TBS-T (10 mM
Tris-HCl, pH 7.8; 100 mM NaCl; 0.05% Tween20), and
digested with 50 μg/ml PK (Invitrogen, Carlsbad, CA) in
TBS-T (10 mM Tris-HCl, pH 7.8; 100 mM NaCl; 0.1%
Tween20) for a period of 2.5 h at 55°C. Sections were
then fixed for 10 min using 4% paraformaldehyde and
then processed for a-syn immunohistochemistry as
described above.
Autoradiography The levels of striatal DAT binding
were assessed by [125I]-RTI-121 binding autoradiography
in sections prepared from fresh-frozen tissue. Briefly,
thawed slides (one slide per animal) were placed in
binding buffer (2 × 15 min, room temperature) contain-
ing 50 mM Tris, 120 mM NaCl and 5 mM KCl. Sec-
tions were then placed in the same buffer containing 30
pM [125I]-RTI-121 (Perkin-Elmer, specific activity 2200
Ci/μmol) for 120 min at 25°C to determine total bind-
ing. Non-specific binding was defined as that observed
in the presence of 100 μM GBR 12909 (Tocris
Bioscience). All slides were then washed (4 × 15 min) in
ice-cold binding buffer, rinsed in ice-cold distilled water
and air-dried. Together with [125I]-microscale standards
(Amersham) slides were then apposed to autoradio-
graphic film (Kodak) and left for 7 days at RT before
developing. Autoradiograms were analysed using MCID
software (Image Research Inc, Ontario, Canada). Densio-
metric analysis of 3 striata from each animal was carried
out whereby a reference curve of c.p.m. versus optical
density was calculated from b-emitting [14C] micro-scale
standards and used to quantify the intensity of signal as
nCi/g. Background intensity was subtracted from each
reading. Data were then expressed as mean ± s.e.m. sig-
nal intensity for each treatment group. Non-specific
binding was calculated in the same way and subtracted
from the total to give to give specific binding. Non-spe-
cific binding was found to account for <1% of total
binding.
Statistical Analysis
For all statistical comparisons we first used a 1-way
ANOVA, with significance set at P < 0.05. If ANOVA
was significant, all post-hoc tests were conducted using
Tukey’s Multiple Comparison test. Where only two
groups were compared, an unpaired t-test was con-
ducted. Software used to conduct statistical analyses and
graph all data was Prism v. 5.02 (GraphPad, La Jolla,
CA, USA).
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